The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of long-term survivors from four clinical trials examining patients with folate receptor alpha–positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine.
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; AstraZeneca; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Umoja Biopharma; Verastem
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo/Lilly; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Novocure; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; ImmunoGen; MSD; Seagen
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Pharma& (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Menarini
(OPTIONAL) Uncompensated Relationships - ENGOT; Gynecological Cancer InterGroup; MITO
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OneXerna Therapeutics, Inc.; PharmaMar; Regeneron; Roche; Seagen; Shattuck Labs; Sutro Biopharma; Zentalis
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche
 
Toon Van Gorp
Consulting or Advisory Role - AstraZeneca (Inst); BioNTech SE (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst); Tubulis GmbH (Inst); Zentalis (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Susana N. Banerjee
Stock and Other Ownership Interests - Perci Health
Honoraria - AstraZeneca; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Novocure; Roche; Takeda; Verastem
Consulting or Advisory Role - Astrazeneca; Epsilogen; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Myriad Genetics; Novartis; OncXerna Therapeutics; Regeneron; Seagen; Shattuck Labs; Verastem (I); Zymeworks
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Verastem
(OPTIONAL) Uncompensated Relationships - ESMO
 
Antonio González-Martín
No Relationships to Disclose
 
Conleth G. Murphy
Honoraria - Daiichi Sankyo Europe GmbH; Janssen Oncology; Janssen Oncology
Travel, Accommodations, Expenses - Bayer; Ipsen; Pfizer
 
Nikolaus de Gregorio
No Relationships to Disclose
 
Gottfried E. Konecny
Consulting or Advisory Role - GOG Partners
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Immunogen; Merck
Research Funding - Lilly (Inst); Merck (Inst)
Expert Testimony - Foundation Medicine
Travel, Accommodations, Expenses - TORL
 
Michael W. Method
Employment - Immunogen
Stock and Other Ownership Interests - Immunogen; Lilly
 
Yuemei Wang
Employment - Immunogen
 
Robert L. Coleman
Employment - US Oncology; Vaniam Group
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson/US Oncology Network
Consulting or Advisory Role - Abbvie; Agenus; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck; Novocure; OncoMed; OncXerna Therapeutics
Research Funding - Alkermes; Amgen (Inst); AstraZeneca/MedImmune; Clovis Oncology (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (I)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Ursula A. Matulonis
Honoraria - Alkermes; Symphogen
Consulting or Advisory Role - Agenus; Allarity Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Curelab Oncology; Eisai; GlaxoSmithKline; GlaxoSmithKline; Immunogen; Lilly; Merck; NextCure; ProfoundBio; Tango Therapeutics
Speakers' Bureau - Med Learning Group
Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; Immunogen
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - AADi; aadi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Duality Biologics (Inst); Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; Regeneron; VBL Therapeutics; Verastem/Pharmacyclics; zentalis
Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
Other Relationship - GOG Partners (Inst)
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novocure; Nuvation Bio; OCXERNA; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novocure; Nuvation Bio; OCXERNA; Pieris Pharmaceuticals; Roche/Genentech
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; MSD Oncology
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Corcept Therapeutics; GlaxoSmithKline